BHCM
RGNX icon

Boulder Hill Capital Management’s Regenxbio RGNX Stock Holding History

Boulder Hill Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-35,396
Closed -$708K – 142
2023
Q2 		$708K Buy
+35,396
New +$682K 1.36% 8

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boulder Hill Capital Management's RGNX Position: Q3 2023 in Review

Boulder Hill Capital Management sold out of Regenxbio (RGNX) in Q3 2023, closing a stake of 35,396 shares — an estimated $708K sold.

Boulder Hill Capital Management first reported a position in RGNX in Q2 2023 and held it in 1 quarter. The position peaked at $708K in Q2 2023. 159 funds tracked by Wall St. Rank hold RGNX as of Q3 2023.

  • Boulder Hill Capital Management reported no remaining Regenxbio position as of Q3 2023 after selling out during the quarter.
  • Boulder Hill Capital Management sold 35,396 Regenxbio shares in Q3 2023, an estimated $708K.
  • Boulder Hill Capital Management first reported a position in Regenxbio in Q2 2023 and held it in 1 quarter.
  • Boulder Hill Capital Management's Regenxbio position peaked at $708K in Q2 2023.
  • 159 funds tracked by Wall St. Rank held Regenxbio as of Q3 2023.

Based on Boulder Hill Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.